IS2811B - Notkun á HPV16 og HPV18 veirulíkum ögnum gegn einni eða fleiri af æxlisvaldandi HPV gerðum 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 - Google Patents

Notkun á HPV16 og HPV18 veirulíkum ögnum gegn einni eða fleiri af æxlisvaldandi HPV gerðum 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Info

Publication number
IS2811B
IS2811B IS7885A IS7885A IS2811B IS 2811 B IS2811 B IS 2811B IS 7885 A IS7885 A IS 7885A IS 7885 A IS7885 A IS 7885A IS 2811 B IS2811 B IS 2811B
Authority
IS
Iceland
Prior art keywords
hpv16
tumor
hpv types
particles against
hpv18 virus
Prior art date
Application number
IS7885A
Other languages
English (en)
Icelandic (is)
Other versions
IS7885A (is
Inventor
Gary Dubin
Bruce Innis
Moncef M Slaoui
M A C Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IS7885A publication Critical patent/IS7885A/is
Publication of IS2811B publication Critical patent/IS2811B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IS7885A 2002-12-20 2005-06-09 Notkun á HPV16 og HPV18 veirulíkum ögnum gegn einni eða fleiri af æxlisvaldandi HPV gerðum 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 IS2811B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20
PCT/EP2003/014562 WO2004056389A1 (en) 2002-12-20 2003-12-18 Hpv-16 and -18 l1 vlp vaccine

Publications (2)

Publication Number Publication Date
IS7885A IS7885A (is) 2005-06-09
IS2811B true IS2811B (is) 2012-11-15

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7885A IS2811B (is) 2002-12-20 2005-06-09 Notkun á HPV16 og HPV18 veirulíkum ögnum gegn einni eða fleiri af æxlisvaldandi HPV gerðum 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Country Status (28)

Country Link
US (2) US20060251676A1 (enExample)
EP (1) EP1572233B1 (enExample)
JP (1) JP5475939B2 (enExample)
KR (3) KR101361769B1 (enExample)
AP (1) AP2005003347A0 (enExample)
AR (1) AR042530A1 (enExample)
AT (1) ATE503492T1 (enExample)
AU (1) AU2003293942B2 (enExample)
BE (3) BE2015C068I2 (enExample)
BR (1) BR0317544A (enExample)
CA (1) CA2510457C (enExample)
CY (1) CY1111552T1 (enExample)
DE (1) DE60336581D1 (enExample)
DK (1) DK1572233T3 (enExample)
EA (2) EA200701633A1 (enExample)
EC (1) ECSP055869A (enExample)
IL (1) IL169085A (enExample)
IS (1) IS2811B (enExample)
MA (1) MA27581A1 (enExample)
MX (1) MXPA05006764A (enExample)
MY (1) MY144492A (enExample)
NO (1) NO20052846L (enExample)
NZ (1) NZ540811A (enExample)
OA (1) OA13147A (enExample)
PL (1) PL215257B1 (enExample)
PT (1) PT1572233E (enExample)
TW (1) TWI349557B (enExample)
WO (1) WO2004056389A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
PL1758609T3 (pl) * 2004-06-16 2013-02-28 Glaxosmithkline Biologicals Sa Szczepionka przeciw HPV16 i HPV18 oraz co najmniej jednemu HPV innego typu wybranemu spośród HPV 31, 45 lub 52
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
SG159525A1 (en) * 2005-04-26 2010-03-30 Glaxosmithkline Biolog Sa Vaccine
MX2007013475A (es) * 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
EP2147926B1 (en) 2007-04-29 2016-08-24 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
WO2008134934A1 (fr) * 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéine l1 tronquée du papillomavirus 16 humain
CA2754533C (en) * 2009-03-05 2019-07-09 Jenny Colleen Mccloskey Treatment of infection
AU2009348078B2 (en) 2009-06-19 2013-03-14 Eyegene Inc. Vaccine for cervical cancer
CN106461667A (zh) 2014-01-31 2017-02-22 乌利塞生物医药公司 用于检测感染及相关病症的生物传感器
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
BR112017008280A2 (pt) 2014-10-24 2018-01-02 Hpvvax, Llc. método para o tratamento de um paciente
CN107614009A (zh) * 2015-06-02 2018-01-19 泰尔茂株式会社 含有铝的佐剂组合物及包含其的疫苗组合物
EP3762022A4 (en) * 2018-03-06 2022-06-15 Precigen, Inc. HUMAN PAPILLOMAVIRUS VACCINES AND USES THEREOF
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
CN110551182A (zh) * 2018-06-04 2019-12-10 厦门大学 一种人乳头瘤病毒18型l1蛋白的突变体
AU2019393770B2 (en) 2018-12-03 2025-02-20 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
DK1015561T3 (da) 1997-09-05 2006-11-13 Medimmune Inc In vitro-fremgangsmåde til adskillelse/gensamling af papillomavirus-lignende partikler (VLP'er)
ES2313881T3 (es) * 1999-02-05 2009-03-16 MERCK & CO., INC. Formulaciones de vacunas frente al papilomavirus humano.
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
PT1296711E (pt) * 2000-06-26 2006-08-31 Stressgen Biotechnologies Corp E7 de vph para o tratamento do virus do papiloma humano

Also Published As

Publication number Publication date
AR042530A1 (es) 2005-06-22
HK1085378A1 (en) 2006-08-25
TWI349557B (en) 2011-10-01
AP2005003347A0 (en) 2005-06-30
BE2015C068I2 (enExample) 2024-08-08
EA200500834A1 (ru) 2006-02-24
MA27581A1 (fr) 2005-10-03
KR20050086924A (ko) 2005-08-30
EP1572233B1 (en) 2011-03-30
PT1572233E (pt) 2011-06-07
KR20120118087A (ko) 2012-10-25
US20060251676A1 (en) 2006-11-09
NO20052846L (no) 2005-07-13
AU2003293942A1 (en) 2004-07-14
WO2004056389A1 (en) 2004-07-08
ECSP055869A (es) 2005-09-20
NZ540811A (en) 2007-03-30
EA009179B1 (ru) 2007-12-28
AU2003293942B2 (en) 2009-12-10
CA2510457A1 (en) 2004-07-08
JP5475939B2 (ja) 2014-04-16
MY144492A (en) 2011-09-30
PL215257B1 (pl) 2013-11-29
MXPA05006764A (es) 2005-09-08
KR101361769B1 (ko) 2014-02-10
CY1111552T1 (el) 2015-08-05
ATE503492T1 (de) 2011-04-15
PL377710A1 (pl) 2006-02-06
EA200701633A1 (ru) 2007-12-28
OA13147A (en) 2006-12-13
IL169085A0 (en) 2007-07-04
US20050287161A1 (en) 2005-12-29
DK1572233T3 (da) 2011-06-27
IS7885A (is) 2005-06-09
JP2006512413A (ja) 2006-04-13
BE2015C069I2 (enExample) 2024-08-08
EP1572233A1 (en) 2005-09-14
KR20120123616A (ko) 2012-11-08
BE2015C067I2 (enExample) 2024-08-08
DE60336581D1 (de) 2011-05-12
IL169085A (en) 2014-04-30
CA2510457C (en) 2011-12-06
TW200423957A (en) 2004-11-16
BR0317544A (pt) 2005-11-22

Similar Documents

Publication Publication Date Title
IS2811B (is) Notkun á HPV16 og HPV18 veirulíkum ögnum gegn einni eða fleiri af æxlisvaldandi HPV gerðum 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
NO2012016I1 (no) Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler
AU2003251604A8 (en) Viruses and virus-like particles for multiple antigen and target display
NO20053357D0 (no) Dyrkingsmedium, dyrkingsmetode og de oppnadde myoblaster og deres anvendelse.
AU2002247689A1 (en) Influenza viruses with enhanced transcriptional and replicational capacities
HUS1500061I1 (hu) A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
AU2002307971A1 (en) Vaccine against the nile fever virus
DE60230162D1 (de) Polymerisate und ihre verwendung
DK1491553T3 (da) Peptider til behandling af cancer forbundet med human papillomavirus (HPV) og andre epitheliale tumorer
AU2003290012A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
AU2002212049A1 (en) Novel silicone material, its preparation method and the use thereof
EP1368058A4 (en) VIRAL REPORTER PARTICLES
IL179138A0 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31,45, or 52
SI1572233T1 (sl) Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
IS7705A (is) 4-(3,5-Dísýanófenoxý) pýrasól afleiður til notkunar sem bakritunarstillar við meðhöndlun á m.a. eyðniveirunni
FI20020375A0 (fi) Menetelmä viruksen kaltaisten partikkeleiden (VKP) tuottamiseksi, plasmidikonstrukti sekä menetelmän käytöt
IS7624A (is) Aðferð við losun íláts, og notkun þeirrar aðferðar
ATE346870T1 (de) Natürlicher antikörper mit wirkung gegen das hiv virus
WO2007044610A3 (en) Virus-like particles and methods of use
HK1103634A (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
CY2015048I1 (el) Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
KR100522448B1 (ko) Hiv 유사입자 및 그 용도
Tofighi Treasury of Aristasias
HK1068353A (en) Molecules that block viral infectivity and methods of use thereof
AU2002341316A1 (en) Molecules that block viral infectivity and methods of use thereof